Premium
FDA approves generic Strattera
Publication year - 2017
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30229
Subject(s) - computer science , business
On May 30, the U.S. Food and Drug Administration approved the first generic versions of Strattera (atomoxetine) to treat attention‐deficit hyperactivity disorder (ADHD) in pediatric and adult patients.